-
-
Approval By The U.S. Fda For Clinical Trial Of The Mrna Herpes Zoster Vaccine Its Humoral And Cellular Immunity Was Significantly Higher Than Those Of Internationally Commercially Available Recombinant Subunit Vaccines
2025-03-24The clinical trial approval for the mRNA herpes zoster vaccine has been recently received from the U.S. Food and Drug Administration (“FDA”). This is the second innovative vaccine product of the Group approved by the U.S. FDA for clinical trials, following the mRNA RSV vaccine, which marks a new milestone in the Group’s globalization strategy.
-
-
Significant Decrease In Loss Of The Company’S Results
2025-03-18The Group is expected to record an unaudited revenue ranging from RMB1.25 billion to RMB1.3 billion for the Reporting Period, representing an increase ranging from RMB60 million to RMB110 million or 5% to 9% as compared to the revenue of RMB1.19 billion for the previous year; and the Group is expected to record an unaudited net loss ranging from RMB250 million to RMB290 million, representing a significant decrease in loss ranging from RMB1.66 billion to RMB1.7 billion or 85% to 87% as compared to the net loss of RMB1.95 billion in the previous year.
-
-
Phase-1 clinical test for mRNA COVID-19 vaccine of AIM Vaccine is in smooth progress, manifesting a high safety and tolerance
2021-09-11 -
By September 9, AIM Vaccine had completed low-dosage and medium-dosage recruitment of adult patients for mRNA COVID-19 vaccine at phase-1 clinical laboratory of Shulan (Hangzhou) Hospital. According to results of preliminary test, the vaccine has manifested a high safety and tolerance after inoculation.
-
-
-
AIM Vaccine enlisted for important contracted project for “Two-zone” construction in Beijing with introduced investments
2021-09-04 -
On the morning of September 3, Zhou Ting, Board Chairman and CEO of AIM Vaccine Co., Ltd attended “One-day for Beijing” and anniversary celebration of “Two-zone” construction at 2021 China International Fair for Trade in Services under invitation, and participated in the signing ceremony for “Two-zone” project. PRC head office and phase-1 project innovative vaccine industrialization base of AIM Vaccine have been listed as important contracted projects for “two-zone” construction in Beijing with introduced investments through strict screening. It is one of 37 key projects completed contract conclusion with Beijing Economic-Technological Development Area t the site on the current day.
-
-
-
AIM COVID-19 vaccine achieved critical progress in industrialization
2021-07-21 -
Ningbo Rong’an Biological Pharmaceutical Co., Ltd, the wholly owned subsidiary of AIM Vaccine has recently obtained Approval Form of Clinical Trial as approved and issued by National Medical Products Administration.
-
-
-
AIM Vaccine completed acquisition of Lifanda to accelerate deployment of mRNA COVID-19 Vaccine
2021-06-01 -
On May 31, AIM Vaccine Co., Ltd completed acquisition of Zhuhai Lifanda Biology Co., Ltd, holding 50.1546% of its shares. Lifanda Biology is one of 3 enterprises obtained clinical approval of mRNA COVID-19 vaccine.
-
